Sonus Pharmaceuticals Awarded Patent for TOCOSOL(R) Camptothecin, the Company's Second Oncology Product Candidate
13 Junio 2007 - 7:30AM
Business Wire
Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced the
issuance of a patent for its second oncology product candidate,
TOCOSOL� Camptothecin. The newly issued patent, United States
Patent No. 7,223,770 entitled �Tocopherol-Modified Therapeutic Drug
Compounds,� is directed to tocopherol-linked prodrugs of
camptothecin and camptothecin derivatives. TOCOSOL Camptothecin is
in a Phase 1 clinical trial that was initiated in September 2006.
Formulated with Sonus� proprietary vitamin-E based TOCOSOL
technology, TOCOSOL Camptothecin is a novel camptothecin compound
that is a conjugate of SN-38. SN-38 is the active ingredient in
irinotecan, a marketed camptothecin analog. Preclinical data
suggest that TOCOSOL Camptothecin may be more effective and better
tolerated than irinotecan, and will be easier and more convenient
to administer. �The granting of this patent for our second drug
candidate is an important milestone as we continue to execute our
strategy of becoming a multiple product oncology company,� said
Michael A. Martino, President and Chief Executive Officer of Sonus
Pharmaceuticals. �With pivotal Phase 3 data expected in the third
quarter of 2007 for TOCOSOL Paclitaxel, our lead product candidate,
coupled with the potential for TOCOSOL Camptothecin and additional
preclinical pipeline opportunities, we are continuing our
commitment to build a portfolio of innovative drugs that will
provide added benefits for cancer patients.� The full text and
claims of the TOCOSOL Camptothecin patent may be found by
conducting a patent number search utilizing the U.S. Patent
Office�s web site at www.uspto.gov/patft/. About Sonus
Pharmaceuticals Located near Seattle, Washington, Sonus
Pharmaceuticals, Inc. is focused on the development of cancer drugs
that are designed to provide better efficacy, safety and
tolerability, and are more convenient to use. The Company�s lead
product candidate, TOCOSOL Paclitaxel, is currently in a Phase 3
pivotal trial for the potential treatment of metastatic breast
cancer. Adjudicated data from the Phase 3 trial are expected to be
available in the third quarter of 2007. TOCOSOL Paclitaxel is an
injectable, ready-to-use formulation of paclitaxel that may reduce
treatment-limiting side effects and improve anti-tumor activity. In
addition to the continuing development of TOCOSOL Paclitaxel, Sonus
moved its second product candidate, TOCOSOL Camptothecin, into a
Phase 1 clinical trial in September 2006. For additional
information on Sonus, including past news releases, please visit
www.sonuspharma.com. Safe Harbor Certain statements made in this
press release are forward-looking such as those, among others,
relating to the development, safety and efficacy of therapeutic
drugs and potential applications for these products. As discussed
in Sonus Pharmaceuticals' filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for 2006 and
subsequent Quarterly Reports on Form 10-Q, actual results could
differ materially from those projected in the forward-looking
statements as a result of the following factors, among others:�the
Company's products will require extensive clinical testing and
approval by regulatory authorities; such approvals are lengthy and
expensive and may never occur; risks that the Company will not be
able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel;
risks that clinical studies with TOCOSOL Paclitaxel will be delayed
or will not be successful; risks that the FDA may not approve the
TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1
clinical trial for TOCOSOL Camptothecin will not be successful;
risks of successful development of therapeutic drugs; and risks
that the Company may not be successful in obtaining funding from
third parties or completing a financing necessary to support the
costs and expenses of clinical studies as well as research and
development activities. The Company undertakes no obligation to
update the forward-looking statements contained herein or to
reflect events or circumstances occurring after the date hereof.
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sonus Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Sonus Pharmaceuticals, Inc. ArtÃculos de Noticias